Page 95 - 202001
P. 95

Pharmacogenetic considerations for optimizing tacrolimus  555-560.
             dosing in liver and kidney transplant patients[J]. World J  [17]  石伟龙,唐惠林,翟所迪. CYP3A4*1G 基因多态性对肾
             Gastroenterol,2013,19(48):9156-9173.               移植受者他克莫司给药剂量及血药浓度影响的系统评
        [ 6 ]  MIANO TA,FLESCH JD,FENG R,et al. Early tacrolim-  价[J].中国临床药理学杂志,2015,31(4):292-296.
             us concentrations after lung transplant are predicted by  [18]  CHO JH,YOON YD,PARK JY,et al. Impact of cyto-
             combined clinical and genetic factors and associated with  chrome P450 3A and ATP-binding cassette subfamily B
             acute kidney injury[J]. Clin Pharmacol Ther,2019.DOI:  member 1 polymorphisms on tacrolimus dose-adjusted
             10.1002/cpt.1629.                                  trough concentrations among Korean renal transplant re-
        [ 7 ]  刘璐,宋沧桑,张阳,等. MDR1 C3435T基因多态性与肾                  cipients[J]. Transplant Proc,2012,44(1):109-114.
             移植患者他克莫司血药浓度关系的Meta分析[J].中国医                  [19]  MIURA M,SATOH S,KAGAYA H,et al. Impact of the
             院药学杂志,2018,38(23):2440-2446.                       CYP3A4*1G polymorphism and its combination with
        [ 8 ]  中华医学会器官移植学分会.中国肺移植免疫抑制治疗                         CYP3A5 genotypes on tacrolimus pharmacokinetics in re-
             及排斥反应诊疗规范:2019 版[J].中华移植杂志(电子                      nal transplant patients[J]. Pharmacogenomics,2011,12
             版),2019,13(2):94-98.                               (7):977-984.
        [ 9 ]  CALABRESE DR,FLOREZ R,DEWEY K,et al. Geno-  [20]  ZHOU LY,ZUO XC,CHEN K,et al. Significant impacts
             types associated with tacrolimus pharmacokinetics impact  of CYP3A4*1G and CYP3A5*3 genetic polymorphisms
             clinical outcomes in lung transplant recipients[J]. Clin  on the pharmacokinetics of diltiazem and its main metabo-
             Transplant,2018,32(8):e13332.                      lites in Chinese adult kidney transplant patients[J]. J Clin
        [10]  GRIFFITH BP,BANDO K,HARDESTY RL,et al. A pro-     Pharm Ther,2016,41(3):341-347.
             spective randomized trial of FK506 versus cyclosporine  [21]  HEBERT MF.Contributions of hepatic and intestinal me-
             after human pulmonary transplantation[J]. Transplanta-  tabolism and P-glycoprotein to cyclosporine and tacrolim-
             tion,1994,57(6):848-851.                           us oral drug delivery[J]. Adv Drug Deliv Rev,1997,27(2/
        [11]  TREEDE H,GLANVILLE AR,KLEPETKO W,et al. Ta-       3):201-214.
             crolimus and cyclosporine have differential effects on the  [22]  WANG J,ZEEVI A,MCCURRY K,et al. Impact of AB-
             risk of development of bronchiolitis obliterans syndrome:  CB1(MDR1)haplotypes on tacrolimus dosing in adult
             results of a prospective,randomized international trial in  lung transplant patients who are CYP3A5 *3/*3 non-ex-
             lung transplantation[J]. J Heart Lung Transplant,2012,31  pressors[J]. Transpl Immunol,2006,15(3):235-240.
            (8):797-804.                                   [23]  LUNDE I,BREMER S,MIDTVEDT K,et al. The influ-
        [12]  GUETHOFF S,MEISER BM,GROETZNER J,et al.           ence of CYP3A,PPARA,and POR genetic variants on the
             Ten-year results of a randomized trial comparing tacrolim-  pharmacokinetics of tacrolimus and cyclosporine in renal
             us versus cyclosporine A in combination with mycopheno-  transplant recipients[J]. Eur J Clin Pharmacol,2014,70
             late mofetil after heart transplantation[J]. Transplantation,  (6):685-693.
             2013,95(4):629-634.                           [24]  徐雯,张晓庆,樊军卫,等.肺移植术后受体CYP3A5和白
        [13]  BRUNET M,VAN GELDER T,ÅSBERG A,et al. Thera-      介素-10 基因多态性与他克莫司个体化用药的关系[J].
             peutic drug monitoring of tacrolimus-personalized thera-  中国药房,2015,26(35):4931-4934.
             py:second consensus report[J]. Ther Drug Monit,2019,41  [25]  朱琳,宋洪涛,王庆华,等. CYP3A4*18B 和 CYP3A5*3
            (3):261-307.                                        基因多态性对肾移植患者他克莫司剂量及浓度的影响
        [14]  LIU F,OU YM,YU AR,et al. Long-term influence of   [J].药学学报,2012,47(7):878-883.
             CYP3A5,CYP3A4,ABCB1,and NR1I2 polymorphisms   [26]  DEININGER KM,VU A,PAGE RL,et al. CYP3A phar-
             on tacrolimus concentration in Chinese renal transplant re-  macogenetics and tacrolimus disposition in adult heart
             cipients[J]. Genet Test Mol Biomarkers,2017,21(22):  transplant recipients[J]. Clinical Transplantation,2016,30
             663-673.                                           (9):1074-1081.
        [15]  ZHANG JJ,LIU SB,XUE L,et al. The genetic polymor-  [27]  卫泽武,王学彬,张文文,等. CYP3A5*3 基因多态性对
             phisms of POR*28 and CYP3A5*3 significantly influence  稳定期肾移植受者他克莫司血药浓度及肾功能的影响
             the pharmacokinetics of tacrolimus in Chinese renal trans-  [J].中国药房,2018,29(2):183-187.
             plant recipients[J]. Int J Clin Pharmacol Ther,2015,53  [28]  周红,张菁,伍三兰,等. CYP3A4/5、POR 基因多态性与
            (9):728-736.                                        中国成年心脏移植受者他克莫司血药浓度相关性的研
        [16]  LUO X,ZHU LJ,CAI NF,et al. Prediction of tacrolimus  究[J].中国药学杂志,2017,52(19):1710-1714.
             metabolism and dosage requirements based on CYP3A4         (收稿日期:2019-07-31   修回日期:2019-10-03)
             phenotype and CYP3A5*3 genotype in Chinese renal                                   (编辑:邹丽娟)
             transplant recipients[J]. Acta Pharmacol Sin,2016,37(4):



        中国药房    2020年第31卷第1期                                               China Pharmacy 2020 Vol. 31 No. 1  ·85  ·
   90   91   92   93   94   95   96   97   98   99   100